Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Rachel Brough(Institute of Cancer Research), Jessica Frankum(Institute of Cancer Research), Iwanka Kozarewa(AstraZeneca (United Kingdom)), Sean Hooper(Institute of Cancer Research), James Campbell(Proteome Sciences (United Kingdom)), Rumana Rafiq(Institute of Cancer Research), Lina Chen(Wellcome Sanger Institute), Rachael Natrajan, David Sims(Institute of Cancer Research), Rowan Miller(University College Hospital), Ioannis Assiotis(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Farah Rehman(Institute of Cancer Research), Kerry Fenwick(Institute of Cancer Research), Asha Konde(Institute of Cancer Research)
Cited by 367
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788